Cabaletta Bio Closes $50 Million Series B Financing to Establish Translational Research and Advanced Manufacturing Capabilities for Chimeric AutoAntibody Receptor (CAAR) T Cell Products to Treat B Cell-Mediated Autoimmune Diseases

from Venture Capital Access Online: Latest Venture Capital and Private Equity News http://bit.ly/2AwguJl
via IFTTT